Literature DB >> 20425417

Chronic myelogenous leukemia stem cells: What's new?

Mhairi Copland1.   

Abstract

Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that arises in the hematopoietic stem cell compartment. CML is one of the best-understood malignancies, as it results from a single genetic mutation, the fusion oncogene BCR-ABL, which has been widely studied. Specific tyrosine kinase inhibitors have been developed to target BCR-ABL in CML, but these agents fail to eliminate the CML stem cell population and thus are unlikely to cure CML. This article reviews recent developments in the biology and treatment of CML, specifically focusing on CML stem cells. Significant progress continues to be made in our understanding of CML stem cell biology, which has wider implications within the cancer stem cell field. We are also beginning to see the identification of novel therapies that specifically target the CML stem cell. These are exciting times in the quest to cure CML.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20425417     DOI： 10.1007/s11899-009-0010-9

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  45 in total

1.  Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.

Authors:  Niove E Jordanides; Heather G Jorgensen; Tessa L Holyoake; Joanne C Mountford
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

Review 2.  Getting to the stem of chronic myeloid leukaemia.

Authors:  Michael Savona; Moshe Talpaz
Journal:  Nat Rev Cancer       Date:  2008-05       Impact factor: 60.716

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Histone deacetylase inhibitors specifically kill nonproliferating tumour cells.

Authors:  Andrew Burgess; Astrid Ruefli; Heather Beamish; Robyn Warrener; Nicholas Saunders; Ricky Johnstone; Brian Gabrielli
Journal:  Oncogene       Date:  2004-09-02       Impact factor: 9.867

5.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Authors:  Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

6.  Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

Authors:  Sarah J Neering; Timothy Bushnell; Selcuk Sozer; John Ashton; Randall M Rossi; Pin-Yi Wang; Deborah R Bell; David Heinrich; Andrea Bottaro; Craig T Jordan
Journal:  Blood       Date:  2007-06-29       Impact factor: 22.113

7.  BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

Authors:  Mhairi Copland; Francesca Pellicano; Linda Richmond; Elaine K Allan; Ashley Hamilton; Francis Y Lee; Roberto Weinmann; Tessa L Holyoake
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

8.  Effect of cellular quiescence on the success of targeted CML therapy.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

9.  CXCR4 is required for the quiescence of primitive hematopoietic cells.

Authors:  Yuchun Nie; Yoon-Chi Han; Yong-Rui Zou
Journal:  J Exp Med       Date:  2008-03-31       Impact factor: 14.307

10.  AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.

Authors:  Liang L Zhou; Yun Zhao; Ashley Ringrose; Donna DeGeer; Erin Kennah; Ann E-J Lin; Guoqing Sheng; Xiao-Jiang Li; Ali Turhan; Xiaoyan Jiang
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307
View more
  9 in total

1.  Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.

Authors:  Gregor Eisenwort; Irina Sadovnik; Alexandra Keller; Daniel Ivanov; Barbara Peter; Daniela Berger; Gabriele Stefanzl; Karin Bauer; Katharina Slavnitsch; Georg Greiner; Karoline V Gleixner; Wolfgang R Sperr; Michael Willmann; Heinz Sill; Peter Bettelheim; Klaus Geissler; Michael Deininger; Thomas Rülicke; Peter Valent
Journal:  Leukemia       Date:  2021-03-30       Impact factor: 12.883

2.  Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.

Authors:  Harald Herrmann; Irina Sadovnik; Gregor Eisenwort; Thomas Rülicke; Katharina Blatt; Susanne Herndlhofer; Michael Willmann; Gabriele Stefanzl; Sigrid Baumgartner; Georg Greiner; Axel Schulenburg; Niklas Mueller; Werner Rabitsch; Martin Bilban; Gregor Hoermann; Berthold Streubel; Daniel A Vallera; Wolfgang R Sperr; Peter Valent
Journal:  Blood Adv       Date:  2020-10-27

3.  CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Authors:  Niklas Mueller; Daniel Wicklein; Gregor Eisenwort; Mohamad Jawhar; Daniela Berger; Gabriele Stefanzl; Georg Greiner; Alexandra Boehm; Christoph Kornauth; Leonhard Muellauer; Susanne Sehner; Gregor Hoermann; Wolfgang R Sperr; Philipp B Staber; Ulrich Jaeger; Johannes Zuber; Michel Arock; Udo Schumacher; Andreas Reiter; Peter Valent
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

4.  Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?

Authors:  Avital F Barak; Lilach Bonstein; Roy Lauterbach; Elizabeth Naparstek; Sigal Tavor
Journal:  Hematol Rep       Date:  2011-12-06

Review 5.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

6.  Identification of a leukemia-initiating stem cell in human mast cell leukemia.

Authors:  Gregor Eisenwort; Irina Sadovnik; Juliana Schwaab; Mohamad Jawhar; Alexandra Keller; Gabriele Stefanzl; Daniela Berger; Katharina Blatt; Gregor Hoermann; Martin Bilban; Michael Willmann; Christiana Winding; Wolfgang R Sperr; Michel Arock; Thomas Rülicke; Andreas Reiter; Peter Valent
Journal:  Leukemia       Date:  2019-04-05       Impact factor: 11.528

7.  Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors.

Authors:  Nawin Manachai; Kasem Rattanapinyopituk; Piyanoot Fonghem; Panrawee Phoomvuthisarn; Shingo Nakahata; Kazuhiro Morishita; Anudep Rungsipipat
Journal:  Vet Med Int       Date:  2022-08-28

Review 8.  The concept of treatment-free remission in chronic myeloid leukemia.

Authors:  S Saußele; J Richter; A Hochhaus; F-X Mahon
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

Review 9.  Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.

Authors:  Peter Valent; Emir Hadzijusufovic; Thomas Grunt; Heidrun Karlic; Barbara Peter; Harald Herrmann; Gregor Eisenwort; Gregor Hoermann; Axel Schulenburg; Michael Willmann; Rainer Hubmann; Medhat Shehata; Edgar Selzer; Karoline V Gleixner; Thomas Rülicke; Wolfgang R Sperr; Brigitte Marian; Michael Pfeilstöcker; Hubert Pehamberger; Felix Keil; Ulrich Jäger; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2018-07-13       Impact factor: 1.704
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.